DUPAN-II normalisation as a biological indicator during preoperative chemoradiation therapy for resectable and borderline resectable pancreatic cancer

DUPAN-II normalisation as a biological indicator during preoperative chemoradiation therapy for resectable and borderline resectable pancreatic cancer

Abstract Background Duke pancreatic mono-clonal antigen type 2 (DUPAN-II) is a famous tumour maker for pancreatic cancer (PC) as well as carbohydrate antigen 19–9 (CA19-9). We evaluated the clinical implications of DUPAN-II levels as a biological indicator for PC during preoperative chemoradiation t...

Full description

Bibliographic Details
Main Authors: Shinichiro Hasegawa, Hidenori Takahashi, Hirofumi Akita, Yosuke Mukai, Manabu Mikamori, Kei Asukai, Daisaku Yamada, Hiroshi Wada, Yoshiaki Fujii, Takahito Sugase, Masaaki Yamamoto, Tomohira Takeoka, Naoki Shinno, Hisashi Hara, Takashi Kanemura, Naotsugu Haraguchi, Junichi Nishimura, Chu Matsuda, Masayoshi Yasui, Takeshi Omori, Hiroshi Miyata, Masayuki Ohue, Osamu Ishikawa, Masato Sakon
Format: Article
Language:English
Published: BMC 2023-01-01
Series:BMC Cancer
Subjects:
DUPAN-II
Pancreas
Cancer
Preoperative chemoradiation therapy
Online Access:https://doi.org/10.1186/s12885-023-10512-2

Internet

https://doi.org/10.1186/s12885-023-10512-2

Similar Items